Can an anti-fracture agent heal fractures?

Clinical Cases in Mineral and Bone Metabolism

Volumn 7, Issue 1, 2010, Pages 11-14

  Einhorn, Thomas A ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bisphosphonates; Denosumab; Fracture healing; Parathyroid hormone; Teriparatide

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENOSUMAB; ETIDRONIC ACID; IBANDRONIC ACID; INCADRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

BONE DEVELOPMENT; BONE DISEASE; BONE MASS; BONE METABOLISM; BONE METASTASIS; BONE REMODELING; CALCIFICATION; CALLUS; CARTILAGE; CATABOLISM; CHONDROGENESIS; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; FIBROUS DYSPLASIA; FRACTURE; FRACTURE HEALING; FRACTURE NONUNION; HUMAN; HYPERCALCEMIA; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PRECURSOR; REVIEW; WEIGHT BEARING;

EID: 77953303190     PISSN: 17248914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Fleisch H. Bisphosphonates: Mechanisms of action. Endocr Rev. 1998;19:80-100.
2. Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone diseease. Drugs. 1991;42:919-944,
3. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25:97-106.
4. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical featurs and mortality after hip fracture. N Engl J Med. 2007;357:1799-1809.
5. Morris CD, Einhorn TA. Bisphosphonates in orthopaedic surgery. J Bone Joint Surg Am. 2005;87:1609-1618.
6. Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP binding proteins, including Ras. J Boner Miner Res. 1998;13:581-589.
7. Fisher JE, Rogers MJ, Halasy JM, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resportion, and kinase activation in vitro. Proc Natl Acad Sci USA. 1999;96:133-138.
8. Fleisch H. Can bisphosphonates be given to patients with fractures? J Bone Miner Res. 2001;16:437-440.
9. Goodship AE, Walker PC, McNally D, et al. Use of a bisphosphonate (pamidronate) to modulate fracture repair in ovine bone. Ann Oncol. 1994;(5 suppl 7):S53-55.
10. Peter CP, Cook WO, Nunamaker DM. et al. Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res. 1996;14:74-79.
11. Li C, Mori SJ, Li J, et al. Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats. J Bone Miner Res. 2001;16:429-436. (Pubitemid 32173356)
12. Amanat N, Brown R, Bilston LE, et al. A single systemic dose of pamidronate improves bone mineral content and accelerates restoration of strength in a rat model of fracture repair. J Orthop Res. 2005;23:1029-1034. (Pubitemid 41245425)
13. Kakar S, Little D, Einhorn TA. Can we improve fixation and outcomes in the treatment of femoral neck fractures? The use of pharmaceuticals? J Orthop Trauma. 2009:1-9.
14. Juppner H, Kronenberg HM. Parathyroid hormone (chapter 18). In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 5th ed. Washington DC: Association of Bone and Mineral Research; 2003:117-124.
15. Podbesek R, Edouard C, Meunier PJ, et al. Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds. Endrocrinology. 1983;112:1000-1006.
16. Hock JM, Gera I. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res. 1992;7:65-71.
17. Andreassen TT, Ejersted C, Oxlund H. Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res. 1999;14:960-968.
18. Andreassen TT, Fledelius C, Ejersted C, et al. Increases in callus formation and mechanical strength of healing rat fractures. Acta Orthop Scand. 2001;72:304-307.
19. Alkhiary YM, Gerstenfeld LC, Krall E, et al. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am. 2005;87:731-741. (Pubitemid 40489347)
20. Nakajima A, Shimoji N, Shiomi K, et al. Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34). J Bone Miner Res. 2002;17:2038-2047. (Pubitemid 35239205)
21. Kakar S, Einhorn TA, Vora S, et al. Enhanced chondrogenesis and Wnt-signaling in parathyroid hormone treated fractures. J Bone Miner. Res. 2007; 22:1903-1912.
22. Biscegli LDBL, Fata G. The use of teriparatide in the treatment of diaphyseal pseudoarthrosis of femur in a 68 year old female with left femur fracture. Bone. 2009;44:S358.
23. Yu CT, Wu JK, Chang CC et al. Early callus formation in human hip fracture treated with internal fixation and teriparatide. J Rheumatology. 2008;35:2082-2083.
24. Brosky T, Recknor C, Grant S. The effect of teriparatide therapy on fracture healing in Charcot neuroarthropathy of the lower extremity. Osteoporosis Int. 2005;16:S44.
25. Knecht TP. Teriparatide and fracture healing in cortical bone. Endocr Pract. 2004;10:293.
26. Aspenberg P, Genant H K, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective randomized, double-blind study of 102 postmenopausal women with distal radius fractures: J Bone Miner Res, Epub, July 13, 2009.
27. Cummings SR, San Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65.
28. Gerstenfeld LC, Sacks DJ, Pelis M, et al. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res 2009;24:196-208.